Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Related Citations for PubMed (Select 18775604)

1.

Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France.

Roux P, Villes V, Bry D, Spire B, Feroni I, Marcellin F, Carrieri MP.

Addict Behav. 2008 Dec;33(12):1625-9. doi: 10.1016/j.addbeh.2008.07.018. Epub 2008 Aug 3.

PMID:
18775604
2.

Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.

Roux P, Villes V, Blanche J, Bry D, Spire B, Feroni I, Carrieri MP.

Drug Alcohol Depend. 2008 Sep 1;97(1-2):105-13. doi: 10.1016/j.drugalcdep.2008.03.025. Epub 2008 May 13.

PMID:
18479840
3.

Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.

Winstock AR, Lea T, Sheridan J.

Int J Drug Policy. 2008 Dec;19(6):450-8. doi: 10.1016/j.drugpo.2007.03.002. Epub 2008 Mar 21.

PMID:
18359216
4.

[Prescription of high dose buprenorphine by general practitioners].

Feroni I, Paraponaris A, Aubisson S, Bouhnik A, Masut A, Ronfle E, Coudert C, Mabriez JC; et le groupe Bupré MG 13.

Rev Epidemiol Sante Publique. 2004 Dec;52(6):511-22. French.

PMID:
15741914
5.

The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group.

Addiction. 2008 Nov;103(11):1828-36. doi: 10.1111/j.1360-0443.2008.02323.x. Epub 2008 Sep 4.

PMID:
18778390
6.

Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study.

Gallagher AM, Leighton-Scott J, van Staa TP.

Clin Ther. 2009 Aug;31(8):1707-15. doi: 10.1016/j.clinthera.2009.08.022.

PMID:
19808129
7.

The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.

Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L.

Int J Drug Policy. 2011 Mar;22(2):167-71. doi: 10.1016/j.drugpo.2010.10.004. Epub 2010 Nov 27.

PMID:
21112758
8.

[Addictive behavior after starting buprenorphine maintenance treatment].

Fanello S, Daoud S, Panici JY, Parot E, Hitoto H, Garnier F.

Presse Med. 2006 Feb;35(2 Pt 1):212-8. French.

PMID:
16493349
9.

Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.

Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O'Connor PG, Schottenfeld RS.

J Gen Intern Med. 2007 Apr;22(4):527-30.

11.

[Absence of correlation between mental disorders and high-dose buprenorphine. A case-control study].

Phan O, Sanchez M, Bouthillon-Heitzmann P.

Presse Med. 2005 Jun 4;34(10):711-8. French.

PMID:
16026124
12.

Buprenorphine prescription by general practitioners in a French region.

Thirion X, Lapierre V, Micallef J, Ronflé E, Masut A, Pradel V, Coudert C, Mabriez JC, Sanmarco JL.

Drug Alcohol Depend. 2002 Jan 1;65(2):197-204.

PMID:
11772481
13.

Why buprenorphine is so successful in treating opiate addiction in France.

Fatseas M, Auriacombe M.

Curr Psychiatry Rep. 2007 Oct;9(5):358-64. Review.

PMID:
17915074
14.

Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France.

Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A.

Drug Alcohol Depend. 2003 Mar 1;69(2):175-81.

PMID:
12609698
15.

[High-dose buprenorphine substitution during incarceration. Management of opiate addicts].

Revnaud-Maurupt C, Caer Y, Escaffre N, Gagneau M, Galinier A, Marzo JN, Meroueh F.

Presse Med. 2005 Apr 9;34(7):487-90. French.

PMID:
15902999
16.

Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence.

Lavie E, Fatséas M, Denis C, Auriacombe M.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):338-44. doi: 10.1016/j.drugalcdep.2008.07.017. Epub 2008 Sep 27.

PMID:
18824311
17.

[Collaboration between general practitioners and pharmacists in the management of patients on high-dosage buprenorphine treatment. Prescribers' practices].

Feroni I, Aubisson S, Bouhnik AD, Paraponaris A, Masut A, Coudert C, Obadia Y.

Presse Med. 2005 Oct 8;34(17):1213-9. French.

PMID:
16230961
18.

Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S.

Ann Fam Med. 2007 Mar-Apr;5(2):146-50.

19.

Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.

Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, Jie S, Mardiati R, Mokri A, Moskalewicz J, Newcombe D, Poznyak V, Subata E, Uchtenhagen A, Utami DS, Vial R, Zhao C.

Addiction. 2008 Sep;103(9):1484-92. doi: 10.1111/j.1360-0443.2008.02249.x. Epub 2008 Jul 10.

PMID:
18636999
20.

Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.

Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, Spire B.

Clin Infect Dis. 2009 Nov 1;49(9):1433-40. doi: 10.1086/630209.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk